Literature DB >> 30150480

Attributable Cost and Length of Stay Associated with Nosocomial Gram-Negative Bacterial Cultures.

Richard E Nelson1,2, Vanessa W Stevens3,2, Makoto Jones3,2, Karim Khader3,2, Marin L Schweizer4,5, Eli N Perencevich4,5, Michael A Rubin3,2, Matthew H Samore3,2.   

Abstract

Few studies have estimated the excess inpatient costs due to nosocomial cultures of Gram-negative bacteria (GNB), and those that do are often subject to time-dependent bias. Our objective was to generate estimates of the attributable costs of the underlying infections associated with nosocomial cultures by using a unique inpatient cost data set from the U.S. Department of Veterans Affairs that allowed us to reduce time-dependent bias. Our study included data from inpatient admissions between 1 October 2007 and 30 November 2010. Nosocomial GNB-positive cultures were defined as clinical cultures positive for Acinetobacter, Pseudomonas, or Enterobacteriaceae between 48 h after admission and discharge. Positive cultures were further classified by site and level of resistance. We conducted analyses using both a conventional approach and an approach aimed at reducing the impact of time-dependent bias. In both instances, we used multivariable generalized linear models to compare the inpatient costs and length of stay for patients with and without a nosocomial GNB culture. Of the 404,652 patients included in the conventional analysis, 12,356 had a nosocomial GNB-positive culture. The excess costs of nosocomial GNB-positive cultures were significant, regardless of specific pathogen, site, or resistance level. Estimates generated using the conventional analysis approach were 32.0% to 131.2% greater than those generated using the approach to reduce time-dependent bias. These results are important because they underscore the large financial burden attributable to these infections and provide a baseline that can be used to assess the impact of improvements in infection control.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Gram-negative bacteria; antimicrobial resistance; burden; cost; health care-associated infections; length of stay

Mesh:

Substances:

Year:  2018        PMID: 30150480      PMCID: PMC6201096          DOI: 10.1128/AAC.00462-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Association between implementation of a medical team training program and surgical mortality.

Authors:  Julia Neily; Peter D Mills; Yinong Young-Xu; Brian T Carney; Priscilla West; David H Berger; Lisa M Mazzia; Douglas E Paull; James P Bagian
Journal:  JAMA       Date:  2010-10-20       Impact factor: 56.272

2.  Resistant gram-negative bacilli: A neglected healthcare crisis?

Authors:  Ebbing Lautenbach; Ron E Polk
Journal:  Am J Health Syst Pharm       Date:  2007-12-01       Impact factor: 2.637

3.  The Effect of a Nationwide Infection Control Program Expansion on Hospital-Onset Gram-Negative Rod Bacteremia in 130 Veterans Health Administration Medical Centers: An Interrupted Time-Series Analysis.

Authors:  Michihiko Goto; Amy M J O'Shea; Daniel J Livorsi; Jennifer S McDanel; Makoto M Jones; Kelly K Richardson; Brice F Beck; Bruce Alexander; Martin E Evans; Gary A Roselle; Stephen M Kralovic; Eli N Perencevich
Journal:  Clin Infect Dis       Date:  2016-06-28       Impact factor: 9.079

4.  Estimating the cost of health care-associated infections: mind your p's and q's.

Authors:  Nicholas Graves; Stephan Harbarth; Jan Beyersmann; Adrian Barnett; Kate Halton; Ben Cooper
Journal:  Clin Infect Dis       Date:  2010-04-01       Impact factor: 9.079

Review 5.  Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs.

Authors:  Craig A Umscheid; Matthew D Mitchell; Jalpa A Doshi; Rajender Agarwal; Kendal Williams; Patrick J Brennan
Journal:  Infect Control Hosp Epidemiol       Date:  2011-02       Impact factor: 3.254

6.  Economic Analysis of Veterans Affairs Initiative to Prevent Methicillin-Resistant Staphylococcus aureus Infections.

Authors:  Richard E Nelson; Vanessa W Stevens; Karim Khader; Makoto Jones; Matthew H Samore; Martin E Evans; R Douglas Scott; Rachel B Slayton; Marin L Schweizer; Eli L Perencevich; Michael A Rubin
Journal:  Am J Prev Med       Date:  2016-05       Impact factor: 5.043

7.  Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections.

Authors:  Rajiv Jain; Stephen M Kralovic; Martin E Evans; Meredith Ambrose; Loretta A Simbartl; D Scott Obrosky; Marta L Render; Ron W Freyberg; John A Jernigan; Robert R Muder; LaToya J Miller; Gary A Roselle
Journal:  N Engl J Med       Date:  2011-04-14       Impact factor: 91.245

8.  A combined comorbidity score predicted mortality in elderly patients better than existing scores.

Authors:  Joshua J Gagne; Robert J Glynn; Jerry Avorn; Raisa Levin; Sebastian Schneeweiss
Journal:  J Clin Epidemiol       Date:  2011-01-05       Impact factor: 6.437

9.  Effect of healthcare-acquired infection on length of hospital stay and cost.

Authors:  Nicholas Graves; Diana Weinhold; Edward Tong; Frances Birrell; Shane Doidge; Prabha Ramritu; Kate Halton; David Lairson; Michael Whitby
Journal:  Infect Control Hosp Epidemiol       Date:  2007-02-20       Impact factor: 3.254

10.  Multistate point-prevalence survey of health care-associated infections.

Authors:  Shelley S Magill; Jonathan R Edwards; Wendy Bamberg; Zintars G Beldavs; Ghinwa Dumyati; Marion A Kainer; Ruth Lynfield; Meghan Maloney; Laura McAllister-Hollod; Joelle Nadle; Susan M Ray; Deborah L Thompson; Lucy E Wilson; Scott K Fridkin
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

View more
  1 in total

1.  Impact of multi-drug resistant bacteria on economic and clinical outcomes of healthcare-associated infections in adults: Systematic review and meta-analysis.

Authors:  Miquel Serra-Burriel; Matthew Keys; Carlos Campillo-Artero; Antonella Agodi; Martina Barchitta; Achilleas Gikas; Carlos Palos; Guillem López-Casasnovas
Journal:  PLoS One       Date:  2020-01-10       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.